“Let's stop criticizing our banks!”

More than ten years after the subprime mortgage crisis, all the light has not been shed, and yet the idea of ​​the guilt of the banks has taken hold firmly in people's minds. They are even blamed for the double fault, since after playing with fire and triggering the crisis, they allegedly asked for help from the States. This unanimous condemnation, the result of incomplete analyzes, is a heavy component of the bank bashing that has raged since then and unfortunately works against our interests. We are indeed at a critical moment when Europe, faced with the domination of American finance and the dollar, must develop its own financial capacities. The development of a strong pan-European financial sector is therefore essential if we particularly want to foster the emergence of future European gafas. 
If it is vain to hope for the complete disappearance of this bank bashing and, one might say, of the bashing market whose roots plunge both in history and in ignor…

Tocilizumab, a treatment to treat severe cases of Covid-19?

The Public Assistance-Hospitals of Paris (AP-HP) unveiled the promising results of its study this Monday, April 27. A promising essay? The immunomodulatory drug tocilizumab has shown its effectiveness in preventing the "inflammatory storm" in Covid-19 patients in serious condition, according to a French study not yet published, the first results of which were released on Monday, April 27. This treatment reduced "significantly" the proportion of patients who had to be transferred to intensive care or died, compared to those who received standard treatment, said the Assistance public-hospitals of Paris.
 
Tocilizumab, a treatment to treat severe cases of Covid-19?

This is the "first comparative trial by lot" which "demonstrates a clinical benefit" of this treatment in Covid patients suffering from severe infection, said its organizers during a conference of telephone press. These results have yet to be "consolidated" and will be published in a scientific journal in a few weeks. But the AP-HP explains that it has decided to make them public now "for reasons of public health", due to the context of the pandemic crisis, and to have communicated them to the French health authorities and to the World Health Organization ( WHO).

Tocilizumab (Actemra or RoActemra), from the Roche laboratory, belongs to the family of monoclonal antibodies - antibodies created in the laboratory, derived from a single strain of lymphocytes and designed to respond to a specific target. Usually used in the treatment of rheumatoid arthritis, it works by blocking the receptor of a protein of the immune system which plays an important role in the inflammatory process.



129 people included in the study

Some patients with the new coronavirus experience a sudden worsening of their condition after several days, causing acute respiratory distress, a phenomenon probably linked to an excessive immune reaction of the body. 129 people hospitalized in 13 hospitals were included in the study: Covid patients suffering from "moderate to severe" pneumonia who needed oxygen assistance. This profile corresponds to "only 5% to 10% of patients infected" with the coronavirus, but they are among those who are most at risk of being placed on artificial respiration or dying, said Xavier Mariette, co-investigator study coordinator, during the conference call.

Half of the participants received one or two tocilizumab injections in addition to the standard treatment (oxygen, antibiotics and anticoagulants), while the other half received only standard care. They were then followed for 14 days to obtain these intermediate results, a follow-up which will continue to confirm the conclusions. At this stage, the researchers did not observe more undesirable side effects in the patients who received the immunomodulator than in those who received the standard treatment, underlined Prof. Mariette.



Other teams have already reported encouraging results concerning tocilizumab, at Foch hospital in particular, but these were "open" studies, without a randomized control group, which did not bring "the same level of evidence "and" do not allow to define a standard of treatment ", underlined the researchers of the AP-HP. The current cost of tocilizumab is around 800 euros per injection, a high price but much lower than that of a day of hospitalization in an intensive care unit, they said. A comparable drug, sarilumab (Kevzara), developed by Sanofi and Regeneron is also being tested in the same clinical trial program, called CORIMMUNO, and the first results should be known "within the next few days", according to Pr Mariette.